多黏菌素的研究进展及临床应用  

Research Progress and Clinical Application of Polymyxins

作　　者：赵保红 陈瑞玲[2] ZHAO Bao-hong;CHEN Rui-ling(Department of Pharmacy,Zhengzhou Second People's Hospital,Zhengzhou Henan 450000,China;Department of Pharmacy,Beijing Tiantan Hospital ,Capital Medical University,Beijing 100050,China)

机构地区：[1]郑州市第二人民医院药务科,河南郑州450000 [2]首都医科大学附属北京天坛医院药学部,北京100050

出　　处：《药品评价》2019年第8期17-22,共6页Drug Evaluation

摘　　要：随着抗菌药物的广泛使用,多重耐药或泛耐药革兰氏阴杆性菌的感染率越来越高,尤其是肺炎克雷伯杆菌、鲍曼不动杆菌和铜绿假单胞菌。多黏菌素作为一种早期抗革兰氏阴性杆菌的药物,由于其凸显出对革兰氏阴性耐药菌的治疗优势,而成为该类感染的最后一道防线。本文就目前的研究从多黏菌素的化学结构、作用机制、药效学和药动学、安全性、耐药性、临床应用及药学监护等方面进行综合分析,以期对临床用药提供参考。With the widespread use of antibiotics, the infection rate of multidrug-resistant or extensively drug-resistant Gram-negative bacteria is increasing, especially Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa. Polymyxin, as an early anti-Gram-negative bacterium drug, has become the last line of defense for this kind of infection because it highlights the advantages of the treatment of Gram-negative resistant bacteria. In this paper, the chemical structure, mechanism of action, pharmacodynamics and pharmacokinetics, safety, drug resistance, clinical application and pharmaceutical care of polymyxins were comprehensively analyzed in order to provide reference for clinical drug use.

关 键 词：多黏菌素 多重耐药或泛耐药革兰氏阴性杆菌 研究进展 临床应用 

分 类 号：R978.1[医药卫生—药品]